MeritValue

CNBX Pharmaceuticals Inc.

CNBXdata completeness 75%21 fiscal years on file

Data notes: no data for concept 'capex'; no data for concept 'totalDebt'

The thesis, from the filings

CNBX Pharmaceuticals Inc. earns about -202% on equity, and has bought back 35% of its shares over 5 years. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$01$29,9582$410,1653$130,0744$04
Net income−$3.19M5−$3.72M6−$3.71M7−$695,1988−$313,9768
Operating cash flow−$2.49M9−$1.68M10−$112,52111−$244,26912−$171,30512
Capital expenditure—————
Free cash flow (derived)—————
Total debt—————
Cash & equivalents$1.39M13$117,51514$129,69615$26,41616$15,11116
Diluted shares138.5M1.2M8.8M30.2M90.6M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.28
your share of equity
Profit it earned you last year
−$0.03
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on −$0.28 of net worth that earned you −$0.03 last year.

iii. Is this a good business?
Moat signal · return on equity
-202% avg · 5y
FY21 -177%FY22 -228%FY23 —FY24 —FY25 —

It earned an average -202% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
−35% shares · 5y

Share count is down 35% over 5 years — management has been buying back stock, quietly handing owners a bigger slice.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-08-31 · accession 0001683168-21-006005 (Revenues)
  2. 10-K · period ending 2022-08-31 · accession 0001683168-23-008557 (Revenues)
  3. 10-K · period ending 2023-08-31 · accession 0001683168-24-008433 (Revenues)
  4. 10-K · period ending 2024-08-31 · accession 0001683168-25-008736 (Revenues)
  5. 10-K · period ending 2021-08-31 · accession 0001683168-22-008095 (NetIncomeLoss)
  6. 10-K · period ending 2022-08-31 · accession 0001683168-23-008557 (NetIncomeLoss)
  7. 10-K · period ending 2023-08-31 · accession 0001683168-24-008433 (NetIncomeLoss)
  8. 10-K · period ending 2024-08-31 · accession 0001683168-25-008736 (NetIncomeLoss)
  9. 10-K · period ending 2021-08-31 · accession 0001683168-22-008095 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2022-08-31 · accession 0001683168-23-008557 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2023-08-31 · accession 0001683168-24-008433 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2024-08-31 · accession 0001683168-25-008736 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K · period ending 2021-08-31 · accession 0001683168-22-008095 (CashAndCashEquivalentsAtCarryingValue)
  14. 10-K · period ending 2022-08-31 · accession 0001683168-23-008557 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2023-08-31 · accession 0001683168-24-008433 (CashAndCashEquivalentsAtCarryingValue)
  16. 10-K · period ending 2024-08-31 · accession 0001683168-25-008736 (CashAndCashEquivalentsAtCarryingValue)